Name
AS Bravo Pharmaceuticals
Registry code
14159974
VAT number
EE101938974
Type
AS - Joint Stock Company
Status
Registered
Foundation date
29.11.2016 (7)
Financial year
01.01-31.12
Capital
163 337.00 €
Activity
86909 - Other healthcare activities not classified elsewhere
-
-
-
-
-
-
Not submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Rakesh Pandey 10.12.1977 (46) | - | Board member | Direct ownership | Founder |
| Reena Singh 13.03.1978 (46) | - | Board member | - | |
| Nishant Kumar 18.10.1983 (41) | - | - | - | Board member |
| Ivo Nagel 07.09.1977 (47) | - | - | - | Chairman of the board |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Competence Centre for Cancer Research AS 11015418 | 65% - 32 500.00 EUR | - | - | Shareholder |
| 2019 21.09.2021 | 2020 12.10.2021 | 2021 21.06.2022 | 2022 26.09.2023 | |
|---|---|---|---|---|
| Total Revenue | 22 429 € | 52 458 € | 30 158 € | 4 775 € |
| Net profit (loss) for the period | -24 959 € | -48 043 € | -57 313 € | -100 122 € |
| Profit Margin | -111% | -92% | -190% | -2097% |
| Current Assets | 96 961 € | 47 456 € | 62 375 € | 56 781 € |
| Fixed Assets | 69 942 € | 251 515 € | 266 505 € | 250 602 € |
| Total Assets | 166 903 € | 298 971 € | 328 880 € | 307 383 € |
| Current Liabilities | 8 554 € | 56 507 € | 143 729 € | 109 217 € |
| Non Current Liabilities | 40 042 € | 0 € | 0 € | 0 € |
| Total Liabilities | 48 596 € | - | - | - |
| Share Capital | 50 000 € | 50 200 € | 50 200 € | 163 337 € |
| Equity | 118 307 € | 242 464 € | 185 151 € | 198 166 € |
| Employees | 2 | 2 | 2 | 2 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 10 674.39 € | 7 012.62 € | 4 791.49 € | 1 |
| 2023 Q4 | 14 556.66 € | 7 123.14 € | 4 685.49 € | 1 |
| 2023 Q3 | - | 6 807.84 € | 5 697.15 € | 1 |
| 2023 Q2 | - | 4 141.31 € | 3 636.73 € | 1 |
| 2023 Q1 | - | 5 485.08 € | 4 590.69 € | 1 |
| 2022 Q4 | - | 5 518.67 € | 4 613.79 € | 1 |
| 2022 Q3 | - | 5 376.45 € | 4 574.19 € | 1 |
| 2022 Q2 | 4 000 € | 5 377.45 € | 4 574.19 € | 1 |
| 2022 Q1 | 15 775 € | 5 453.08 € | 4 574.19 € | 1 |
| 2021 Q4 | 4 000 € | 5 528.27 € | 4 620.39 € | 1 |
| 2021 Q3 | 6 041.66 € | 5 011.18 € | 4 027.65 € | 1 |
| 2021 Q2 | 5 116.66 € | 4 475.82 € | 3 754.38 € | 1 |
| 2021 Q1 | - | 4 136.41 € | 3 754.38 € | 2 |
| 2020 Q4 | - | 4 076.41 € | 3 765.51 € | 2 |
| 2020 Q3 | 17 024.27 € | 2 903.4 € | 3 536.89 € | 2 |
| 2020 Q2 | 7 933.34 € | 5 483.39 € | 4 135.88 € | 2 |
| 2020 Q1 | 29 333.33 € | 2 337.85 € | 2 067.94 € | 2 |
